Literature DB >> 32097616

Label-free peptide quantification coupled with in silico mapping of proteases for identification of potential serum biomarkers in gastric adenocarcinoma patients.

Talita Mendes de Oliveira1, José Thalles Jocelino Gomes de Lacerda2, Giuseppe Gianini Figueiredo Leite2, Meriellen Dias3, Maria Anita Mendes3, Paulo Kassab4, Clisleyd Glaucielly Sales E Silva5, Maria Aparecida Juliano5, Nora Manoukian Forones6.   

Abstract

OBJECTIVES: We aimed to identify serum level variations in protein-derived peptides between patients diagnosed with gastric adenocarcinoma (GAC) and non-cancer persons (control) to detect the activity changes of proteases and explore the auxiliary diagnostic value in the context of GAC physiopathology.
METHODS: The label-free quantitative peptidome approach was applied to identify variants in serum levels of peptides that can differentiate GAC patients from the control group. Peptide sequences were submitted against Proteasix tool predicting proteases potentially involved in their generation. The activity change of proteases was subsequently estimated based on the peptides with significantly altered relative abundance. In turn, activity change prediction of proteases was correlated with relevant protease expression data from the literature.
RESULTS: A total of 191 peptide sequences generated by the cleavage of 36 precursor proteins were identified. Using the label-free quantification approach, 33 peptides were differentially quantified (adjusted fold change ≥ 1.5 and p-value < 0.05) in which 19 were up-regulated and 14 were down-regulated in GAC samples. Of these peptides, fibrinopeptide A was significantly decreased and its phosphorylated form ADpSGEGDFLAEGGGVR was upregulated in GAC samples. Activity change prediction yielded 10 proteases including 6 Matrix Metalloproteinases (MMPs), Thrombin, Plasmin, and kallikreins 4 and 14. Among predicted proteases in our analysis, MMP-7 was presented as a more promising biomarker associated with useful assays of clinical practice for GAC diagnosis.
CONCLUSION: Our experimental results demonstrate that the serum levels of peptides were significantly differentiated in GAC physiopathology. The hypotheses built on protease regulation could be used for further investigations to measure proteases and their activity levels that have been poorly studied for GAC diagnosis.
Copyright © 2020 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Gastric adenocarcinoma; Proteases; Quantitative serum peptidome

Mesh:

Substances:

Year:  2020        PMID: 32097616     DOI: 10.1016/j.clinbiochem.2020.02.010

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  3 in total

1.  A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients.

Authors:  Silvia Marconi; Michela Croce; Giovanna Chiorino; Giovanni Rossi; Francesca Guana; Aldo Profumo; Paola Ostano; Angela Alama; Luca Longo; Giuseppa De Luca; Mariella Dono; Maria Giovanna Dal Bello; Marco Ponassi; Camillo Rosano; Paolo Romano; Zita Cavalieri; Massimiliano Grassi; Marco Tagliamento; Lodovica Zullo; Consuelo Venturi; Chiara Dellepiane; Luca Mastracci; Elisa Bennicelli; Paolo Pronzato; Carlo Genova; Simona Coco
Journal:  Cancers (Basel)       Date:  2022-07-14       Impact factor: 6.575

2.  Differentially expressed serum proteins in children with or without asthma as determined using isobaric tags for relative and absolute quantitation proteomics.

Authors:  Ming Li; Mingzhu Wu; Ying Qin; Huaqing Liu; Chengcheng Tu; Bing Shen; Xiaohong Xu; Hongbo Chen
Journal:  PeerJ       Date:  2020-11-03       Impact factor: 2.984

3.  Biomarkers of connective tissue disease-associated interstitial lung disease in bronchoalveolar lavage fluid: A label-free mass spectrometry-based relative quantification study.

Authors:  Jing Ye; Pengcheng Liu; Renming Li; Hui Liu; Wenjing Pei; Changxiu Ma; Bing Shen; Dahai Zhao; Xiaoyu Chen
Journal:  J Clin Lab Anal       Date:  2022-03-25       Impact factor: 3.124

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.